Yasuyoshi Miyata

By Yasuyoshi Miyata, Hideki Sakai and Shigeru Kanda

Part of the book: Bladder Cancer

By Yasuyoshi Miyata and Hideki Sakai

Part of the book: Advances in the Scientific Evaluation of Bladder Cancer and Molecular Basis for Diagnosis and Treatment

By Yasuyoshi Miyata, Yohei Shida, Tomohiro Matsuo, Tomoaki Hakariya and Hideki Sakai

Hormonal therapy is a major and effective tool in the treatment of prostate cancer patients. This is especially true for patients in the advanced stages of disease. Unfortunately, almost all prostate cancer cells will develop into castration‐resistant prostate cancer (CRPC) despite continued therapy and suppression of testosterone levels. Up until 5–6 years ago, there was little effective therapy for the treatment of CRPC patients. However, recently, a variety of methodologies and drugs such as cabazitaxel and sipuleucel‐T have been approved globally for the treatment of CRPC. Two novel drugs, abiraterone acetate and enzartamide, have also become available as potential treatment options. However, the anticancer effects of these two drugs are not always satisfactory in terms of prolonging survival. These drugs are also associated with adverse events and are expensive when compared with the costs of previously used anticancer drugs. In this section, we pay particular attention to hormonal therapies that do not include the use of abiraterone acetate or enzartamide. We believe that a detailed understanding of the range of currently available hormonal therapies, including their associated benefits and limitations, is important for supporting the prolongation of survival in patients with advanced prostate cancer. Therefore, this section offers a valuable discussion on the treatment strategies for prostate cancer including CRPC.

Part of the book: Prostate Cancer